

MYRIAD GENETICS INC  
Form 8-K  
December 28, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 28, 2004**

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>0-26642</b> (Commission File Number)	<b>87-0494517</b> (IRS Employer Identification No.)
	<b>320 Wakara Way</b> <b>Salt Lake City, Utah 84108</b> (Address of principal executive offices) (Zip Code)	

Registrant's telephone number, including area code: **(801) 584-3600**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 Other Events**

## Edgar Filing: MYRIAD GENETICS INC - Form 8-K

On December 28, 2004, Myriad Genetics, Inc. announced that it has submitted an Investigational New Drug (IND) application to the FDA to begin a Phase I human clinical trial with MPC-2130 (previously referred to as MPI-176716), a broad-acting inducer of apoptosis in cancer cells. The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.

### ITEM 9.01 Financial Statements and Exhibits.

- (c) The following exhibit is filed with this report:

<b>Exhibit Number</b>	<b>Description</b>
99.1	The Registrant's press release dated December 28, 2004.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### MYRIAD GENETICS, INC.

Date: December 28, 2004

By: /s/ PETER D. MELDRUM

Peter D. Meldrum  
President and Chief Executive Officer

3

### EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	The Registrant's press release dated December 28, 2004.

### QuickLinks

[ITEM 8.01 Other Events](#)

[ITEM 9.01 Financial Statements and Exhibits.](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)